ImmunityBio’s (IBRX) commercial portfolio comprises its only marketed drug, Anktiva (N-803, or nogapendekin alfa inbakicept-pmln). Anktiva, in combination with Bacillus Calmette-Guérin (BCG), got FDA approval in April 2024 for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. ImmunityBio’s shares gained 16.7% in the past week following the announcement of insurance coverage for its drug across multiple s ...